This page lists current other NCI and NIH cancer imaging initiatives, including grant mechanisms where industry is encouraged to apply.
The NCI's Division of Extramural Activities provides information about newly approved concepts, which may become RFAs and PAs. Check the Concepts Cleared at the NCI Board of Scientific Advisors Meeting web site for the earliest possible information about future initiatives.
Jiayin (Jerry) Li, M.D., Ph.D.; Phone: 240-276-6210; Email: email@example.com
For contact information for specific areas, please consult the FOA for the complete list.
The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 and R37 (MERIT) research projects for early-stage development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Initiative, this FOA aims to promote interdisciplinary collaboration in the development of innovative computational methods and informatics approaches that are essential for cancer research on all fronts to accelerate scientific discovery and ultimately translate data into knowledge and clinical practice. Applications that focus on data processing and analysis or mathematical/statistical modeling alone without new technology development are not appropriate for this FOA.
Earliest submission date: December 22, 2012
For this FOA, please see http://www.cancer.gov/researchandfunding/contacts for Scientific/Research Contacts at NCI.
Purpose: The National Cancer Institute (NCI) Exploratory/Developmental Grant (R21) funding opportunity supports the development of new research activities in all areas of cancer research. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (biomedical, behavioral, or clinical).